Lumbard & Kellner’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.32M | Hold |
2,520
| – | – | 0.8% | 38 |
|
|
2025
Q4 | $2.71M | Hold |
2,520
| – | – | 0.95% | 39 |
|
|
2025
Q3 | $1.92M | Hold |
2,520
| – | – | 0.71% | 44 |
|
|
2025
Q2 | $1.96M | Hold |
2,520
| – | – | 0.86% | 40 |
|
|
2025
Q1 | $2.08M | Sell |
2,520
-573
| -19% | -$477K | 0.92% | 42 |
|
|
2024
Q4 | $2.39M | Hold |
3,093
| – | – | 1.03% | 42 |
|
|
2024
Q3 | $2.74M | Sell |
3,093
-187
| -6% | -$168K | 1.21% | 39 |
|
|
2024
Q2 | $2.97M | Sell |
3,280
-555
| -14% | -$444K | 1.4% | 34 |
|
|
2024
Q1 | $2.98M | Sell |
3,835
-1,530
| -29% | -$1.09M | 1.45% | 30 |
|
|
2023
Q4 | $3.13M | Sell |
5,365
-154
| -3% | -$89.9K | 1.81% | 23 |
|
|
2023
Q3 | $2.96M | Hold |
5,519
| – | – | 1.97% | 21 |
|
|
2023
Q2 | $2.51M | Hold |
5,519
| – | – | 1.4% | 29 |
|
|
2023
Q1 | $2.19M | Hold |
5,519
| – | – | 1.1% | 35 |
|
|
2022
Q4 | $2.02M | Hold |
5,519
| – | – | 0.99% | 35 |
|
|
2022
Q3 | $1.78M | Hold |
5,519
| – | – | 0.92% | 38 |
|
|
2022
Q2 | $1.79M | Hold |
5,519
| – | – | 0.91% | 42 |
|
|
2022
Q1 | $1.58M | Hold |
5,519
| – | – | 0.62% | 45 |
|
|
2021
Q4 | $1.35M | Hold |
5,519
| – | – | 0.51% | 47 |
|
|
2021
Q3 | $1.27M | Hold |
5,519
| – | – | 0.5% | 51 |
|
|
2021
Q2 | $1.27M | Hold |
5,519
| – | – | 0.49% | 50 |
|
|
2021
Q1 | $1.01M | Hold |
5,519
| – | – | 0.35% | 53 |
|
|
2020
Q4 | $1.15M | Sell |
5,519
-370
| -6% | -$55.2K | 0.45% | 53 |
|
|
2020
Q3 | $768K | Sell |
5,889
-66
| -1% | -$10.2K | 0.38% | 47 |
|
|
2020
Q2 | $978K | Hold |
5,955
| – | – | 0.56% | 38 |
|
|
2020
Q1 | $826K | Hold |
5,955
| – | – | 0.55% | 40 |
|
|
2019
Q4 | $783K | Hold |
5,955
| – | – | 0.4% | 45 |
|
|
2019
Q3 | $666K | Hold |
5,955
| – | – | 0.36% | 48 |
|
|
2019
Q2 | $660K | Hold |
5,955
| – | – | 0.35% | 46 |
|
|
2019
Q1 | $773K | Hold |
5,955
| – | – | 0.43% | 41 |
|
|
2018
Q4 | $689K | Hold |
5,955
| – | – | 0.42% | 41 |
|
|
2018
Q3 | $639K | Hold |
5,955
| – | – | 0.33% | 45 |
|
|
2018
Q2 | $508K | Hold |
5,955
| – | – | 0.3% | 44 |
|
|
2018
Q1 | $461K | Hold |
5,955
| – | – | 0.26% | 47 |
|
|
2017
Q4 | $503K | Hold |
5,955
| – | – | 0.26% | 50 |
|
|
2017
Q3 | $509K | Hold |
5,955
| – | – | 0.28% | 54 |
|
|
2017
Q2 | $490K | Hold |
5,955
| – | – | 0.28% | 54 |
|
|
2017
Q1 | $501K | Hold |
5,955
| – | – | 0.3% | 54 |
|
|
2016
Q4 | $438K | Hold |
5,955
| – | – | 0.28% | 48 |
|
|
2016
Q3 | $478K | Hold |
5,955
| – | – | 0.33% | 49 |
|
|
2016
Q2 | $469K | Hold |
5,955
| – | – | 0.35% | 50 |
|
|
2016
Q1 | $429K | Hold |
5,955
| – | – | 0.31% | 49 |
|
|
2015
Q4 | $502K | Buy |
5,955
+2,255
| +61% | +$187K | 0.37% | 47 |
|
|
2015
Q3 | $310K | Sell |
3,700
-300
| -8% | -$25.3K | 0.25% | 53 |
|
|
2015
Q2 | $334K | Hold |
4,000
| – | – | 0.24% | 55 |
|
|
2015
Q1 | $291K | Hold |
4,000
| – | – | 0.21% | 63 |
|
|
2014
Q4 | $276K | Hold |
4,000
| – | – | 0.2% | 66 |
|
|
2014
Q3 | $259K | Hold |
4,000
| – | – | 0.18% | 71 |
|
|
2014
Q2 | $249K | Hold |
4,000
| – | – | 0.18% | 68 |
|
|
2014
Q1 | $204K | Hold |
4,000
| – | – | 0.17% | 64 |
|
|
2013
Q4 | $204K | Buy |
+4,000
| New | +$200K | 0.17% | 64 |
|
Other funds holding LLY
VCM
VPM
Lumbard & Kellner's LLY Position: Q1 2026 in Review
Lumbard & Kellner held its Eli Lilly (LLY) position steady in Q1 2026 at 2,520 shares worth $2.32M. The position accounts for 0.8% of the portfolio, ranked #38.
Lumbard & Kellner first reported a position in LLY in Q4 2013 and has held it in 50 quarters since. The position peaked at $3.13M in Q4 2023. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Lumbard & Kellner held 2,520 shares of Eli Lilly worth $2.32M as of Q1 2026.
- Lumbard & Kellner left its Eli Lilly share count unchanged in Q1 2026.
- Eli Lilly made up 0.8% of Lumbard & Kellner's portfolio in Q1 2026, its #38 holding.
- Lumbard & Kellner first reported a position in Eli Lilly in Q4 2013 and has held it in 50 quarters since.
- Lumbard & Kellner's Eli Lilly position peaked at $3.13M in Q4 2023.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Lumbard & Kellner's 13F filing for Q1 2026, filed 15 May 2026.